quarta-feira, 7 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· July 28, 2026

Walmart (WMT) Stock Could Be Pricey After The Salad Recall

View original at finance.yahoo.com
Walmart (WMT) Stock Could Be Pricey After The Salad Recall Never miss an important update on your stock portfolio and cut through the noise…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The recent salad recall linked to a Cyclospora outbreak may help explain why investors could still assign a quality premium to Walmart, even as food safety headlines potentially add to perceived risk.

    60% confidence
  • With a low valuation score of 1 out of 6 checks, Walmart does not screen as a clear bargain on the broader valuation framework.

    60% confidence
  • Walmart's DCF analysis suggests the stock may be overvalued by 14.6%.

    60% confidence
  • The discounted cash flow analysis indicates that Walmart stock currently looks overvalued relative to its modeled intrinsic value.

    60% confidence
  • The latest DCF estimate points to Walmart shares trading at a premium to intrinsic value, while market-based multiples suggest pricing closer to fair value.

    60% confidence

Data points we hold from this source

Walmart Inc. · intrinsic value per share98.66 USD
Walmart Inc. · free cash flow15.2 USD
Walmart Inc. · valuation score1 out_of_6_checks
Walmart Inc. · dcf premium to intrinsic value14.6 percent
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
A nossa leitura dos dados ›
Sinais que acompanhamos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,985
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,985 factos verificados com a fonte5,351 documentos-fonte arquivados
Consulte estes dados → isubstrate.com